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TYROSINE 370 PHOSPHORYLATION OF ATM POSITIVELY REGULATES 
DNA DAMAGE RESPONSE 
  
Hong-Jen Lee, M.S. 
Advisory Professor: Mien-Chie Hung, Ph.D. 
 
Abstract 
Ataxia telangiectasia-mutated (ATM) mediates DNA damage response by 
controlling irradiation (IR)-induced foci formation, cell cycle checkpoint, and 
apoptosis. However, how upstream signaling regulates ATM is not 
completely understood. Here, we show that upon IR stimulation, ATM 
associates with and is phosphorylated by epidermal growth factor receptor 
(EGFR) at Y370 at the site of double-strand breaks. Depletion of 
endogenous EGFR impairs ATM-mediated foci formation, homologous 
recombination, and DNA repair. Moreover, ATM Y370F mutant or 
pretreatment with an EGFR kinase inhibitor gefitinib blocks EGFR and ATM 
association, hinders CHK2 activation and subsequent foci formation, and 
increases radio-sensitivity. Thus, we reveal a critical mechanism by which 
EGFR directly regulates ATM activation in DNA damage response and ATM 
Y370 phosphorylation may serve as a biomarker for radiation and anti-EGFR 
combinational therapies. 
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CHAPTER 1 INTRODUCTION 
1.1 DNA damage response 
        DNA damage response (DDR) consists of massive signaling network 
and maintains genomic stability when mammalian cells are subjected to 
exogenous damage agents such as: radiation, radiomimetic chemicals, 
cancer therapeutic agents, or endogenous stimuli like reactive oxygen 
species and replication errors (Jackson and Bartek, 2009). Among 
various DNA lesions, DNA double strand breaks (DSBs) formation is one 
of the most injurious lesions to DNA structure and chromatin integrity 
(Bensimon et al., 2011). Proteins involve in DDR can be classified into 
three categories: sensors, transducers and effectors (Zhou and Elledge, 
2000). Sensor proteins in DDR, such as: Ku70-Ku80 heterodimer, Mre11-
Rad50-NBS1 (MRN) complex or γ-H2AX, are those proteins recognize 
broken DNA fragments in a sequence-independent manner and being 
recruited to DNA breaks at early time points after DNA damaged 
(McGowan and Russell, 2004). Then those sensor proteins recruits more 
signal transducers, including three major serine/threonine 
phosphoinositide-3 kinase like kinases (PIKK): ataxia telangiectasia 
mutated (ATM), ATM Rad3-related protein (ATR) and the catalytic subunit 
of DNA-dependent protein kinase (DNA-PKcs), to the DSBs through 
protein-protein interactions (Lempiainen and Halazonetis, 2009). Such 
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protein recruitments and accumulations at DSBs form foci and further 
facilitate signal transduction by post translational modification (PTM). 
Next, transducer proteins initiate series of signaling cascades to 
downstream effectors for execution of cell cycle arrest, DNA repair, foci 
formation, transcription or apoptosis.  
        Although ATM, ATR and DNA-PKcs all serve as important 
transducers in DDR, they are activated by various DNA damage stimuli 
and involved in different signaling pathway (Ditch and Paull, 2012). ATR 
is activated by single stranded DNA lesions formation or collapsed 
replication forks, through binding with ATR-interacting protein (ATRIP), 
and recruited to the region coated by replication protein A (RPA) 
(Cimprich and Cortez, 2008; Flynn and Zou, 2011; Lopez-Contreras and 
Fernandez-Capetillo, 2010; Shiotani and Zou, 2009). ATM and DNA-PKcs 
are both activated by DSBs induction but associating with diverse protein 
complex and initiating different DNA repair signaling pathways. ATM is 
recruited to DSBs by association with MRN complex and activated via 
autophosphorylation at Serine 1981 (S1981) and regulates homologous 
recombination (HR) DNA repair (Derheimer and Kastan, 2010; Lavin and 
Kozlov, 2007; Lee and Paull, 2007).  
        In contract, DNA-PKcs engages in non-homologous end-joining 
(NHEJ) DNA repair through association with Ku70-Ku80 heterodimers at 
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DSBs (Dobbs et al., 2010; Mahaney et al., 2009; Nagasawa et al., 2011). 
However, how mammalian cells command the signaling directions 
between HR (ATM/MRN complex) or NHEJ (DNA-PKcs/Ku heterodimers) 
remains unclear. Accumulating evidence showed that failure of DNA 
repair or impeding appropriate DDR may result into cell death, 
chromosomal deletion, translocation or mutation and then contribute to 
promote tumor initiation. 
 
1.2 Biological functions and significance of ATM 
         Ataxia telangiectasia (A-T) is a rare, inherited neurodegenerative 
disease which results into difficulties of movement and coordination, 
impairment of immune system and predisposition of cancer (Zhang et al., 
1997). Due to missense or nonsense mutation of ATM gene, most A-T 
patients do not possess functional ATM protein kinase which plays a 
critical role in maintaining genomic stability. ATM gene encodes a 350 
kDa protein kinase which consists of N-terminal HEAT (huntingtin, 
elongation factor 1A, protein phosphatase 2A A-subunit, TOR) repeats 
(Perry and Kleckner, 2003), FAT domain (FRAP, ATM and TRRAP; aa 
1960–2566), PI-3 kinase like kinase domain (KD domain, aa 2712–2962) 
and C-terminal FATC (FRAP, ATM and TRRAP C-terminal; aa 2963–
3056) domain (Figure 1).  
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        With treatments of radiation or agents induce DSBs formation, 
inactive ATM homodimer dissociates as active monomer and 
autophosphorylates at Serine 367, Serine 1893, Serine 1981 and Serine 
2996 (Bakkenist and Kastan, 2003; Bensimon et al., 2010; Kozlov et al., 
2011; Kozlov et al., 2006) (Figure 2). Previous studies demonstrated that 
mutations of those ATM autophosphorylation sites disrupt ATM-mediated 
DDR signaling pathways in human cells. However, mouse model of ATM 
mutations and in vitro studies showed that those ATM 
autophosphorylation sites are dispensable for ATM activation by DNA 
damage stimuli or oxidation (Daniel et al., 2008; Guo et al., 2010; Lee and 
Paull, 2005; Pellegrini et al., 2006), suggesting ATM activation may 
require addition regulation mechanisms. 
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Figure 1 The protein kinase structure and post-translational 
modifications of ATM. 
        Schematic representation of ATM protein kinase structure, positions 
of autophosphorylation serine residues (S367, S1893, S1981 and S2996), 
CDK5-mediated phosphorylation residue (S794) and TIP60-mediated 
acetylation residue (K3016). N-term: N-terminal. C-term: C-terminal. 
HEAT repeats: huntingtin, elongation factor 1A, protein phosphatase 2A 
A-subunit, TOR. FAT domain: FRAP, ATM and TRRAP; aa 1960–2566. 
KD domain: PI-3 kinase like kinase domain, aa 2712–2962. FATC domain 
FRAP, ATM and TRRAP C-terminal; aa 2963–3056. 
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 As a serine/threonine kinase, ATM transduces signals in DDR network 
through mediating more than seven hundred putative substrates 
phosphorylation (Matsuoka et al., 2007), which is identified in a global 
proteomic analysis. When recruited to DSBs and associated with MRN 
complex, ATM subsequently phosphorylates checkpoint kinase 2 (CHK2) 
at Serine 68 or p53 at Serine 15 to regulate cell cycle checkpoint or 
apoptosis (Barlow et al., 1997; Matsuoka et al., 2000) (Figure 2). In 
addition to serving as a component of MRN complex which accounts for 
ATM DSBs recruitment, Nijmegen breakage syndrome 1 (NBS1) is also 
an ATM substrate. It had been shown that ATM-mediated NBS1 serine 
278 and serine 343 phosphorylation facilitates structural maintenance of  
chromosome 1 (SMC1) phosphorylation and cell cycle arrest in S phase 
(Kitagawa et al., 2004; Yazdi et al., 2002). 
 
1.3 Post translational modifications of ATM 
        Several important post translational modifications (PTM) which affect 
ATM    functions and activity had been identified by different research 
groups. In post-mitotic neurons, cyclin-dependent kinase 5 (CDK5) 
directly phosphorylates ATM at serine 794 (S794) upon DNA damage 
stimulation (Tian et al., 2009). Mutation of S794 impairs ATM S1981 
autophosphorylation and downstream substrates p53 and H2AX functions. 
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Figure 2 ATM activation and downstream signaling pathways. 
        Upon ionizing radiation (IR) stimulation, inactive homodimer ATM 
dissociates as active monomers and is recruited to DSBs by MRN complex. 
Subsequently, activated ATM transduces signal to downstream substrates 
like p53 or CHK2 through protein-protein interaction and phosphorylation and 
mediates cell cycle arrest for DNA repair. M: Mrell. R: Rad50. N: NBS1. P: 
phosphorylation. 
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Moreover, blockage of CDK5-ATM signaling pathway protects neuron cell 
death induced by DNA damage agents, implying that CDK5 mediating 
ATM S794 phosphorylation plays a critical role in ATM activation. By 
using a systematic  mutagenesis assay, ATM lysine 3016 (K3016) 
acetylation, mediated by Tip60 histone acetyltransferase, was shown to 
be required for ATM activation and downstream p53 or CHK2 
phosphorylation (Sun et al., 2007). Mutation of ATM K3016 not only 
abolishes ATM kinase upregulation but also hinders dissociation of ATM 
inactive homodimer to active monomer, suggesting ATM K3016 
acetylation may play a key role in ATM activation. 
 
1.4 EGFR signaling pathway and cancer 
        The epidermal growth factor receptor (EGFR) is a well-documented 
oncogene and plasma membrane abundant receptor tyrosine kinase 
(RTK) which functions at the upstream of various signaling cascades. It 
belongs to ErbB (erythroblastic leukemia viral oncogene homolog) family 
including EGFR (ErbB-1), HER2 (ErbB-2), ErbB-3 and ErbB-4 (Yarden 
and Sliwkowski, 2001). Ligands, such as epidermal growth factor (EGF), 
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AREG), 
transforming growth factor-α (TGF-α), betacellulin (BTC), epigen (EPG) or 
epiregulin (EPR), stimuli trigger EGFR homodimerization or 
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heterodimerization with other ErbB proteins (Ferguson et al., 2003; 
Garrett et al., 2002; Ogiso et al., 2002; Olayioye et al., 2000; Yarden and 
Sliwkowski, 2001). Such EGFR conformational changes lead to kinase 
activity upregulation and subsequently autophosphorylation at multiple 
tyrosine (Y) residues including Y992, Y1045, Y1068, Y1086, Y1148 and 
Y1173 of the C-terminal region (Linggi and Carpenter, 2006; Olayioye et 
al., 2000; Zhang et al., 2006).  
        EGFR gene mutation or ligands amplification, resulting into EGFR 
signaling upsurge which leads to tumor initiation, progression or 
metastasis, was observed in types of cancer like breast cancer, head and 
neck cancer, lung cancer, colorectal cancer and glioblastoma (Holbro et 
al., 2003; Normanno et al., 2005; Normanno et al., 2006; Uberall et al., 
2008; Zandi et al., 2007). Once activated, EGFR rapidly associates with 
Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain 
containing proteins such as growth factor receptor-bound protein 2 
(GRB2) and recruits a cascade of protein kinase to regulate cell cycle, 
cell survival and proliferation (Yaffe, 2002). The recruitments and 
interactions between EGFR and adaptor proteins like GRB2 initiate 
several signaling networks including: the PI3K-AKT pathway (PI3K, 
phosphoinositide 3-kinase), the RAS-RAF-MEK-ERK pathway (Ras, rat 
sarcoma viral oncogene homologue; RAF,v-raf murine sarcoma viral 
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oncogene homologue; MEK, MAPK/ERK activator kinase; ERK, 
extracellular signal-regulated kinase), the STATs (signal transducer and 
activator of transcription) pathway and the PLCγ-PKC pathway (PLCγ, 
phospholipase C-γ PKC, protein kinase C) which serve critical roles in 
regulation of cancer cell adhesion, migration, invasion, proliferation and 
transformation (Bogdan and Klambt, 2001; Jorissen et al., 2003; Yarden 
and Sliwkowski, 2001; Zandi et al., 2007). Monoclonal antibodies against 
EGFR (targeting extracellular domain) and small molecular chemical 
compounds targeting EGFR kinase domain had been developed and 
used in clinical for cancer patient treatments or combinational therapies 
(Tebbutt et al., 2013). 
 
1.5 Biological functions of nuclear EGFR 
        Other than the role of EGFR in traditional signaling pathways, 
increasing evidence demonstrated by different group of researchers 
showed that some populations of EGFR localizing in the nucleus involve 
in gene transcription, cell proliferation, DNA repair, and chemotherapy or 
radiotherapy resistance in the last decade (Wang and Hung, 2009; Wang 
et al., 2010). Mechanisms triggering plasma membrane bound EGFR 
translocate from cell surface to the nucleus can be classified as two types: 
ligand-dependent and ligand-independent. In response to EGF ligand 
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stimulation, nuclear EGFR associates to the A-T rich sequence (ATRS) 
residing in cyclin D1 promoter, turns on downstream genes expression 
and increases cancer cell proliferation (Lin et al., 2001). Although EGFR 
does not possess DNA binding domain, one group demonstrated that 
nuclear EGFR can target another ATRS in iNOS (inducible nitric oxide 
synthase) promoter region through binding with transcriptional factor 
STAT3 (Lo et al., 2005). Similar to this study, nuclear EGFR was shown 
to transactivate Aurora-A promoter by cooperating with STAT5 and 
amplify Aurora-A gene expression, which leads to chromosomal instability 
and tumorigenesis (Hung et al., 2008).  
        B-MYB is another transcriptional target of nuclear EGFR upon EGF 
stimulation (Hanada et al., 2006). In breast cancer cell, nuclear EGFR 
and E2F1 regulate B-MYB gene expression through targeting B-MYB 
promoter in an EGFR kinase activity dependent manner. As a tyrosine 
kinase, nuclear EGFR was shown to physically associate with PCNA 
(proliferating cell nuclear antigen) and phosphorylate PCNA at tyrosine 
211 (Y211) residue (Wang et al., 2006). They also showed that EGFR-
mediated PCNA Y211 phosphorylation is not only required for chromatin-
bound PCNA stability but also correlates with nuclear EGFR expression 
level, suggesting PCNA Y211 phosphorylation may serve as a marker for 
overall survival rate of breast cancer patient.  
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        When discussing the role of nuclear EGFR, one important issue 
needs to be addressed is how membrane-bound EGFR translocates from 
plasma cell surface to the nucleus. To this point, accumulated data 
showed that early stage of EGFR internalization and the association 
between EGFR and Importin β1 are critical for EGFR nuclear entry 
through nuclear pore complex (Lo et al., 2006). However, the interaction 
between EGFR and exportin CRM1 mediates EGFR nuclear export. 
Besides, a putative nuclear localization sequence (NLS), containing three 
clusters of basic amino acids, identified in EGFR intracellular carboxyl 
terminus participates into EGFR nuclear localization as well (Hsu and 
Hung, 2007). In fact, EGFR is not the only RTK can be found in the 
nucleus among all the ErbB family proteins. It had been shown that full-
length ErbB2 and ErbB3 can both be detected in the nucleus by using 
immunohistochemical (IHC) staining, immunofluorescence staining and 
transmission electron microscopy (TEM). (Offterdinger et al., 2002; Wang 
et al., 2004; Xie and Hung, 1994). 
 
1.6 The role of nuclear EGFR in DNA damage response 
        In ligand-independent pathway, EGFR can be directed to the 
nucleus in response to radiation, UV, H2O2 or therapeutic chemical 
compounds stimuli (Wang and Hung, 2009; Wang et al., 2010). DNA-
13 
 
PKcs, one of the upstream signal transducer in DDR and regulating NHEJ 
repair pathway when DSBs formation, is the most well-documented 
protein involving in nuclear EGFR functions in DDR. In 1998, nuclear 
EGFR was first reported to associate with DNA-PKcs and Ku70-Ku80 
heterodimers in the nucleus by using immunofluorescence staining and 
confocal microscopy (Bandyopadhyay et al., 1998). Pretreatment of c225 
(cetuximab), a monoclonal antibody against EGFR extracellular domain 
not only reduces EGFR kinase activity but impairs DNA-PKcs nuclear 
localization and activity, implying the link between nuclear EGFR and 
DNA-PKcs.  
        Similar phenomenon was observed by different group who studied 
the role of nuclear EGFR in DDR. They found that radiation induces 
EGFR nuclear translocation, association with DNA-PKcs and 
consequently increases DNA-PKcs activity and radiosensitivity of cancer 
cells (Dittmann et al., 2005a; Dittmann et al., 2005b). Blockade of EGFR 
nuclear translocation by monoclonal antibody cetuximab, EGFR and 
HER-2 dual kinase activity inhibitor laptinib or cyclooxygenase-2 (COX-2) 
inhibitor celecoxib impairs DNA-PKcs kinase activity and function in DNA 
repair and sensitizes cancer cells to radiation treatment (Dittmann et al., 
2005b; Dittmann et al., 2008b; Kim et al., 2009). In non-small-cell lung 
cancer cells (NSCLC), mutant EGFR carrying with common oncogenic 
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tyrosine kinase domain mutations, L858R or DeltaE746-E750 elevates 
NSCLC radiosensitivity due to defect of nuclear translocation upon 
radiation treatment, suggesting the significance of nuclear EGFR in 
radiation therapy (Das et al., 2007). 
 
1.7 Combinational therapy of EGFR inhibitors and radiation 
        Since EGFR orchestrates upstream signaling pathways in various 
types of cancer and radiation activating EGFR had been linked to 
radiotherapy resistance, pre-clinical tests which combine EGFR inhibitors 
with radiation therapy had become attractive and been conducted. In 
2005, researchers observed that combination of EGFR kinase inhibitor 
erlotinib (Tarceva) with radiation can increase cell radiosensitivity and 
enhance cell apoptosis. Moreover, systemic administration of erlotinib 
profoundly shrinks tumor size when combining with radiation treatment in 
xenograft mouse model (Chinnaiyan et al., 2005).  
        By using monoclonal antibody cetuximab combining with radiation, 
similar result reported by another group indicated such a combination 
therapy demonstrates a cooperative growth inhibitory effect in certain 
NSCLC cell lines and xenograft mouse model (Raben et al., 2005). 
Another study, which combined with clinically using EGFR kinase inhibitor 
gefitinib and radiation, carried out in NSCLC cell lines showed that 
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gefitinib delays DSBs repair efficiency and increases cell radiosensitivity 
comparing with radiation treatment alone (Tanaka et al., 2008).  
        As a matter of fact, EGFR inhibitors sensitizing cancer cell in 
response to radiation treatment was also observed in head and neck 
squamous-cell carcinoma (HNSCC) cell lines (Harari and Huang, 2001; 
Huang et al., 1999; Huang and Harari, 2000; Loeffler-Ragg et al., 2008; 
Milas et al., 2000). To apply those pre-clinical discoveries to clinical site, a 
multinational, randomized clinical study performed with more than four 
hundred advanced squamous-cell carcinoma of the head and neck 
patients indicated that cetuximab combines with radiotherapy improved 
patient survival rate (Bonner et al., 2006).  
 
1.8 Hypothesis 
        Several lines of evidence have demonstrated that 
autophosphorylation of ATM at S367, S1893, and S1981 are individually 
required for ATM activation and ATM-mediated DDR in human. However, 
more recent studies have indicated that mutation of either the prominent 
S1987 autophosphorylation site (corresponds to S1981 in human) or the 
three conserved autophosphorylation sites S367/S1899/S1987 
(correspond to S367/S1893/S1981 in human) of ATM in mice had no 
effect on ATM-dependent response (Daniel et al., 2008; Pellegrini et al., 
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2006). These findings suggest that other mechanisms may be involved in 
DNA damage-induced activation of ATM in addition to 
S367/S1893/S1981 autophosphorylation. We performed a mass 
spectrometry analysis and identified additional IR-triggered ATM 
phosphorylation at S85, Y370, T1885, S1891, and S2592 (Figure 4A).  
        Since ATM is a serine/threonine kinase, the results suggest that 
ATM Y370 phosphorylation would require a tyrosine kinase and this 
tyrosine kinase may involve in mediation of DDR through regulating this 
ATM Y370 phosphorylation (Figure 3). 
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Figure 3 Model depicting project hypothesis 
        Since our preliminary results showed ATM is tyrosine 
phosphorylated at Y370 in response to IR stimulation, we propose that 
tyrosine kinase (Tyr-kinase) mediating this Y370 phosphorylation event 
may regulate ATM functions in DDR.  P in red circle: ATM 
autophosphorylation S1981. P in purple circle: ATM Y370 
phosphorylation. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Nuclear fractionation, Western blotting and immunoprecipitation 
assays  
        Nuclear fractionation and Western blotting were performed as 
described previously (Yu et al., 2012). Briefly, after serum starvation 
overnight, cells were treated with or without IR, washed with 
phosphate buffer saline (PBS) twice, and resuspended in lysis buffer 
(20 mM HEPES pH7.0, 10 mM KCl, 2 mM MgCl2, 0.5% Nonidet P-40, 
1 mM NaF, 1 mM Na3VO4, 1 mM PMSF, and 2 µg/ml aprotinin) on ice. 
After homogenizing cells with 25-30 strokes in Dounce homogenizer 
and centrifugation at 1,500 x g for 5 min, supernatant was separated 
as cytosolic extract (CE) and nuclear pellets were wash with lysis 
buffer for three times and lysed in TGN buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1% Tween 20, 0.3% NP-40, 1 mM NaF, 1 mM Na3VO4, 
1 mM PMSF, and 1X protease inhibitor mixture; Roche) (Yang and 
Kastan, 2000) with sonication.  
        Both nuclear extracts (NE) and CE were collected from 
supernatant after centrifugation at highest speed for 10 min at 4°C and 
protein concentration was determined by using BCA protein assay kit 
(Thermo Scientific). At least 2 mg of NE was applied to subsequent 
immunoprecipitation (IP) assay. Anti-EGFR (SC-03, 1:1,000; Santa 
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Cruz), anti-ATM (1:1,000; Bethyl Lab), anti-Lamin A (1:2,000; Santa 
Cruz), anti-tubulin (1:10,000; Sigma), anti-Flag (1:2,000; Sigma), anti-
Myc (1:10,000; Roche), anti-phospho-EGFR Y1086 (1:2,000; Cell 
Signaling) and anti-phosphotyrosine  (4G10, 1:3,000; Millipore) 
antibodies were used in western blotting. Antibodies against phospho-
NBS1 S343 (1:2,000; Cell Signaling), NBS1 (1:40,000; Novus), Rad50 
(1:10,000; GeneTex), Mrell (1:20,000; GeneTex), phospho-ATM 
S1981 (1:4,000; R&D system) and ORC2 (1:2,000; Cell Signaling) 
were used in detection of DNA damage response signaling. For 
immunoprecipitation, 5 µg of anti-phosphotyrosine antibody (4G10; 
Millipore), 2 µg of anti-EGFR antibody (Ab-13, Thermo Scientific) or 5 
µg of anti-ATM antibody (Bethyl Lab) was used in 2 mg of nuclear 
extracts, respectively. 
 
2.2 Chromatin enriched fractionation  
        EGFR knockdown (shRNA EGFR #1 and #2) or vector control 
HeLa cells were treated with or without 10 Gy IR. After IR, cells were 
washed by ice-cold PBS twice, resuspended with buffer A (10 mM 
HEPES pH7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% 
glycerol, 1 mM DTT, 0.1% Triton X-100, and 1X protease inhibitor 
cocktail mixture (Roche)) and gentle rotated at 4℃ for 30 min. After 
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centrifugation at 6,500 x g for 5 min, pellets were washed with 1mL 
buffer A (without Triton X-100) once, resuspend with 1 mL of buffer B 
(3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, and 1X protease inhibitor 
mixture), and gently rotated at 4°C for 30 min. After centrifugation at 
6,500 x g for 5 min, pellets were washed with 1 mL of wash bufferⅠ(3 
mM EDTA, 0.2 mM EGTA, 10 mM Tris-HCl, pH8.0, and 150 mM NaCl) 
and gently rotated at 4°C for 15 min. This step was repeated with 
wash buffer Ⅱ (3 mM EDTA, 0.2 mM EGTA, 10 mM Tris-HCl, pH8.0, 
and 250 mM NaCl). Cell pellets were lysed with TGN buffer, sonicated, 
and applied to centrifugation at 16,000 x g for 10 min at 4°C. 
Chromatin-enriched fraction was collected from the supernatant for 
subsequent Western blot analysis. 
 
2.3 Immunofluorescence staining for irradiation-induced foci formation 
        For detection of p-ATM S1981 irradiation-induced foci formation 
(IRIF), EGFR-depleted HeLa cells were exposed to 2 Gy or 10 Gy IR 
and subjected to staining as previously described13. To detect whether 
ATM Y370F impaired p-ATMS1981 or p-CHK2 T68 IRIF, ATM-
depleted HeLa cells were transfected with pcDNA3 vector alone, Flag-
tagged ATM wild type (WT) or Y370F by using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instruction.  
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        Post transfection for 24 h, cell transfectants were seeded on 
cover slides for subsequent IRIF staining as previous procedure. For 
detection of p-CHK2 IRIF, U2OS or HeLa cells were washed with PBS 
three times, fixed and permeabilized as previously described (Peng et 
al., 2009) then subjected to staining. Antibodies against phospho-ATM 
S1981 (1:200; Rockland Immunochemicals), phospho-CHK2 T68 
(1:200; Cell Signaling), Flag (1:200; Cell Signaling), and phospho-
H2AX S139 (1:200; Cell Signaling) were used in detection of IRIF. 
 
2.4 KillerRed system 
        KillerRed (KR; Figure 7D) is a light-stimulated ROS-inducer fused 
to a tet-repressor (tetR-KR), which binds to a TRE cassette (~ 90 kb) 
integrated at a defined genomic locus in U2OS cells (U2OS TRE cell 
line) (Lan et al., 2010). KR facilitates the formation of oxygen radicals 
and superoxide through the excited chromophore (Carpentier et al., 
2009; Pletnev et al., 2009) to induce DNA damage. By targeting the 
expression of KR to one specific genome site, we can visualize the 
recruitment of proteins at genetic loci. To activate KR, tetR-KR was 
exposed to 559 nm laser light for 50 scans (over a total of 10 s) at a 
power rate of 1 mW/scan (equal to 50 mW).  
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        At “the KR-TRE array” induced localized damage, we have 
detected γ-H2AX at the site of tetR-KR but not tetR-monomer cherry 
(tetR-mcherry) after laser light exposure (Lan et al., 2013) For 
bleaching KR, a 559 nm laser (1 mW/scan) in a selected area was 
used (FV1000 SIM Scanner set with 405 nm laser diode, Cat. 
F10OSIM405, Olympus). The dose that was delivered to the KillerRed 
spot was calculated based on the pixel size, the pixel size for 
irradiation is (0.138 um/pixel) and the dwell time per pixel is (8 
us/pixel). The irradiation is at 1.0 mW (1.0 mJ/s). With a dwell time of 
8 us/pixel, this irradiates each pixel with 8.0 nJ/pixel/scan. Multiplying 
by the number of scans gives the total energy per pixel.  
 
2.5 Laser microirradiation 
        The Olympus FV1000 confocal microscopy system was 
employed (Cat. F10PRDMYR-1, Olympus, UPCI facility) and FV1000 
software was used for acquisition of images. For inducing DNA 
damage, cells are irradiation 405 nm laser irradiation. The output 
power of the laser (original 50mW) passed through the lens was 5 
mW/scan. Laser light was passed through a PLAPON 60x oil lens 
(super chromatic abe. corr. obj W/1.4NA FV, Cat. FM1-U2B990). Cells 
were incubated at 37°C on a thermo-plate (MATS-U52RA26 for 
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IX81/71/51/70/50; metal insert, HQ control, Cat. OTH-I0126) in Opti-
MEM during observation to avoid pH change.  
 
2.6 Neutral comet assay 
        Neutral comet assay was carried out to determine the levels of 
DSB in EGFR-depleted and control HeLa cells according to the 
manufacturer’s instruction of Trevigen’s Comet Assay Kit (4250-050-K, 
R&D systems). The comet tail movement was measured by using 
CometScore software (www.autocomet.com) among more than 100 
randomly selected cells in each experiment.  
 
2.7 Cell culture, transient transfection, and viral infection 
        HeLa cell, U2OS cell, and HEK 293T cell were purchased from 
ATCC and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM)/F12 medium supplemented with 10% fetal bovine serum. All 
cell lines are characterized as mycoplasma negative. For transient 
transfection, cells were transfected with indicated plasmids by either 
SN liposome (Zou et al., 2002) or Lipofectamine 2000 (Invitrogen). For 
lentiviral short hairpin RNA (shRNA) infection, HEK 293T cells were 
contransfected with vector control, two various EGFR-targeting or two 
different ATM-targeting shRNA with packing plasmids including 
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deltaVPR8.2 and envelope plasmid VSVG using SN liposome or 
Lipofectamine 2000 according to the manufacturer’s instructions. 
Virus-particles containing media was harvested to infect HeLa cell or 
U2OS cell after 48 h cotransfection. All the infected cells were 
maintained in media containing 0.5 µg/mL puromycin. 
 
2.8 In vitro kinase assay 
        Equal amounts of purified GST, GST-tagged ATM2 or 
ATM2/Y370F protein were incubated with purified recombinant human 
EGFR kinase (#7706, Cell Signaling), 10 µCi  [γ-32P] ATP, 10 µM ATP 
in kinase assay buffer (5 mM MgCl2, 5 mM MnCl2, 50 µM Na3VO4, 50 
mM HEPES, pH7.4, and 5 mM DTT) at 30°C for 30 min. The kinase 
reaction was stopped by addition of SDS samples buffer and boiling. 
The samples were analyzed by SDS-PAGE, transferred to PVDF 
membrane, and detected by autoradiography. To detect EGFR directly 
phosphorylated full-length Flag-tagged ATM, purified Flag-tagged 
ATM protein was incubated with or without purified recombinant 
human EGFR kinase in the kinase assay buffer as previously 
mentioned without [γ-32P] ATP. The resulting signal was detected by 
Western blotting with the indicated antibody. 
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2.9 Chromatin immunoprecipitation assay 
        To detect EGFR or ATM localized at DSB sites, DR-GFP 
integrated U2OS cells were transiently transfected with vector alone or 
I-SceI plasmid as described previously (Peng et al., 2009). After 
transfection for 24 h, transfectants were harvested for nuclear 
fractionation and intact nuclear pellets were collected for crosslink with 
formaldehyde and subsequent ChIP assays by using EZ-ChIP kit 
(Upstate) in accordance with the manufacturer’s instructions. Anti-
EGFR (Thermo Scientific, Ab-13) and anti-pATM S1981 (Rockland 
Immunochemicals) antibodies were used for immunoprecipitation. 
PCR was carried out with primers flanking the I-SceI restriction 
enzyme cutting site shown in Figure 7A. 
 
2.10 Mass spectrometry analysis 
        Exogenous overexpressed Flag-tagged ATM was isolated from 
HeLa cell nuclear extracts by immunoprecipitation using anti-Flag 
antibody and analyzed by SDS-PAGE. To identify novel 
phosphorylation sites on ATM, mass spectrometry analysis was 
carried out as previously described (Liu et al., 2012). 
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2.11 Homologous Recombination (HR) repair analysis 
        To generate EGFR knockdown stable clones, U2OS cells 
containing a single copy of the HR repair reporter substrate DR-GFP 
were infected by lentiviral shRNAs targeting to EGFR or vector control, 
respectively. After 48-h transfection with mock or I-SceI plasmids 
followed by 16-h sodium butyrate (5 mM) treatment, flow cytometry 
analysis was carried out to determine the number of HR-repaired 
GFP-positive cells. 
 
2.12 Colony formation assay 
        HeLa cells were re-plated and exposed to various doses of 
ionizing radiation (IR) the next day. After 10-day culture, cells were 
fixed with Acetic acid:methanol (1:3) solution and colonies were 
stained with 0.5% Crystal violet. The number of colonies was 
quantitated and results were normalized to plating efficiency. 
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CHAPTER 3 ATM IS PHOSPHORYLATED AT TYROSINE 370 (Y370) 
UPON IR STIMULATION 
 
3.1 Identification of ATM phosphorylation sites by Mass spectrometry 
analysis 
        Since recent studies have shown that mutation of either the prominent 
S1987 autophosphorylation site (corresponds to S1981, which 
phosphorylation level serves as ATM activation marker in human cells) or the 
three conserved autophosphorylation sites S367/S1899/S1987 (correspond 
to S367/S1893/S1981 in human) of ATM in mice had no effect on ATM-
dependent downstream signaling (Daniel et al., 2008; Pellegrini et al., 2006). 
These observations suggest that other mechanisms may be involved in DNA 
damage-induced activation of ATM in addition to S367/S1893/S1981 
autophosphorylation.  
        To elucidate unknown ATM phosphorylation sties that may regulate 
ATM functions in DDR, we performed a mass spectrometry analysis and 
identified additional IR-triggered ATM phosphorylation at S85, Y370, T1885, 
S1891, and S2592 (Figure 4A). Among these, S85, T1885 and S1891 have 
been reported by other groups (Bennetzen et al., 2010; Kozlov et al., 2011; 
Matsuoka et al., 2007), which further substantiates the reliability of this mass 
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spectrometry analysis. However, detailed functions of ATM S85, T1885 and 
T1891 in DDR are not clear.  
3.2 ATM Y370 is evolutionary conserved from yeast to mammals 
        Next, we aimed to figure out whether any ATM phosphorylation residue 
we identified in mass spectrometry analysis is evolutionary conserved. 
Between the two novel phosphorylation sites Y370 and S2592 identified, 
Y370 (Figure 4B) was shown to be evolutionary conserved from yeast to 
mammals (but not frog or fruit fly) (Figure 4C), suggesting this Y370 
phosphorylation may involve in mediating functions in DDR. Since ATM is a 
serine/threonine kinase, the results suggest that ATM Y370 phosphorylation 
would require a tyrosine kinase.  
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Figure 4 ATM is phosphorylated at tyrosine 370 (Y370) upon IR 
stimulation. 
A. Mass spectrometry analysis results of immunoprecipitated (IP) 
exogenous Flag-tagged ATM from HeLa cell nuclear extracts after 10 
Gy IR. Sequence: ATM peptide analyzed by mass spectrometry. 
Position: phosphorylation residue on ATM. 
 
 
B. Mass spectrometry image shows ATM is phosphorylated at Y370 
(label as red) after 10Gy IR stimulation. 
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Figure 4 ATM is phosphorylated at tyrosine 370 (Y370) upon IR 
stimulation. 
C. Alignment of ATM partial sequences from human to yeast. Red Y 
indicates human ATM tyrosine 370 (Y370) is conserved among all 
mammalian species and yeast. Frog possesses shorter form of ATM, 
which lacks the N-terminal region. 
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CHAPTER 4 EGFR MEDIATES ATM TYROSINE PHOSPHRYLATION 
 
4.1 Identification of kinase mediating ATM tyrosine phosphorylation 
         To determine which tyrosine kinase might be responsible for ATM 
tyrosine phosphorylation after IR stimulation, we first tested a series of 
tyrosine kinase inhibitors (TKIs) for their effect on ATM tyrosine 
phosphorylation by immunoprecipitation (IP) using 4G10, a pan anti-
phosphotyrosine antibody. Pretreatment with epidermal growth factor 
receptor (EGFR) kinase inhibitors (gefitinib and AG1478) significantly 
decreased ATM tyrosine phosphorylation levels (Figure 5A). In contrast, 
pretreatments with other TKIs, including imatinib, crizotinib, SU4312, 
PD173074, masitinib, and picropodophyllin, did not have any substantial 
effects on ATM tyrosine phosphorylation (Figure 5A). These results suggest 
that EGFR is a potential tyrosine kinase of ATM.  
 
4.2 ATM is phosphorylated by EGFR in vitro and in vivo 
        Next, we asked whether EGFR can directly phosphorylate ATM in vitro. 
Indeed, results from in vitro kinase assay indicated that EGFR directly 
phosphorylated ATM (Figure 5B). In addition, purified human EGFR kinase 
domain directly phosphorylated a recombinant GST-ATM2 fragment 
(residues 250-522) (Khanna et al., 1998) but not the one containing the 
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Y370F mutation (Figures 5C). Moreover, we performed co-
immunoprecipitation (co-IP) assay in 293T cells and found we can only 
detect ATM tyrosine phosphorylation when ATM was co-immunoprecipitated  
with EGFR wild type (Figure 5D). ATM tyrosine phosphorylation signal was 
reduced when co-IP with EGFR kinase dead (KD) mutant or pretreatment of 
EGFR kinase inhibitor gefitinib, which strongly suggests that EGFR is a bona 
fide kinase of ATM. 
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Figure 5 EGFR mediates ATM tyrosine phosphorylation. 
A. Identification of kinase mediating ATM tyrosine phosphorylation. 
        Western blot analysis of HeLa cells nuclear extracts (NE) 
pretreated with vehicle (DMSO) or tyrosine kinase inhibitors (TKIs) as 
indicated, followed by IR stimulation and IP with pan-pTyr antibody 
(4G10). Lamin A and tubulin served as nuclear and cytosolic markers, 
respectively. NE indicates nuclear extract. Imatinib, Bcr-Abl kinase 
inhibitor; crizotinib, lymphoma kinase, c-ros oncogene 1 receptor 
tyrosine kinase (ROS1), and c-Met inhibitor; SU4312, vascular 
endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 
and platelet derived growth factor (PDGF) receptor inhibitor; 
PD173074, fibroblast growth factor receptor inhibitor; masitinib, stem 
cell growth factor receptor (c-kit) and platelet-derived growth factor 
(PDGF) receptor inhibitor; picropodophyllin (PPP), insulin-like growth 
factor-1 (IGF) receptor inhibitor. 
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B. EGFR phosphorylates purified Flag-tagged ATM in vitro. 
        Purified Flag-tagged ATM proteins were incubated with or without 
purified recombinant human EGFR kinase in vitro and analyzed by 
Western blotting with indicated antibodies. 
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Figure 5 EGFR mediates ATM tyrosine phosphorylation. 
C. EGFR phosphorylates purified recombinant GST-ATM2 fragment but 
not GST-ATM2/Y370F mutant. 
        Up panel: schematic of GST only (GST), GST-fused ATM2 and 
GST-ATM2-Y370F (GST-ATM2/Y370F) constructs. ATM2 indicates 
ATM residues 250-522. 
Bottom panel: recombinant GST, GST-ATM2 and GST-ATM2/Y370F 
proteins were incubated with purified recombinant human EGFR 
kinase (His672-Ala1210) in vitro, analyzed by SDS-PAGE, and 
detected by γ-32P exposure (kinase assay) or Coomassie brilliant blue 
staining. 
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Figure 5 EGFR mediates ATM tyrosine phosphorylation. 
D. EGFR kinase activity is required for ATM tyrosine phosphorylation. 
        HEK 293T cells transfected with the indicated plasmids were 
treated by IR stimulation. The resulting cells were harvested for co-
immunoprecipitation followed by Western blot analysis. Gefitinib: 
EGFR kinase inhibitor. 
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CHAPTER 5 EGFR ASSOCIATES WITH ATM IN THE NUCLEUS IN 
RESPONSE TO IR 
 
5.1 Endogenous EGFR associates with ATM in the nucleus upon IR 
stimulation. 
        Previously we found EGFR mediates ATM tyrosine phosphorylation 
upon IR stimulation, so we hypothesize that EGFR may associate with ATM 
in response IR. EGFR has been shown to translocate to the nucleus upon 
various stimuli, including IR (Dittmann et al., 2005a; Dittmann et al., 2008a; 
Wang and Hung, 2009). We demonstrated that IR not only provoked EGFR 
nuclear translocation (Figure 6A) but also induced endogenous EGFR 
association with ATM in the nucleus as determined by immunoprecipitation 
and reciprocal immunoprecipitation assays using anti-EGFR and anti-ATM 
antibodies, respectively, against nuclear extracts (Figures 6B and 6C). 
Meanwhile, pretreatment with gefitinib reduced the interaction between 
EGFR and ATM (Figures 6B and 6C), suggesting the association between 
EGFR and ATM depends on EGFR kinase activity.  
        EGFR is a plasma membrane abundant protein which locates in the 
non-nuclear compartment of cell. We ask whether EGFR binds to ATM in the 
cytosolic fraction. As shown in Figure 6D, immunoprecipitation of EGFR 
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cannot pull down ATM in the cytosolic fraction, suggesting EGFR only 
interacts with ATM in the nucleus. 
 
5.2 EGFR C-terminal CR domain is required for ATM interaction. 
        To identify which domain of EGFR is responsible for interaction with 
ATM, we performed domain mapping of EGFR with ATM by using co-IP 
analysis. Among various functional domains (Figure 6E, up panel), the C-
terminal regulatory region (CR) domain of EGFR seemed to be required for 
its association with ATM (Figure 6E, bottom panel). Together, these results 
indicate that EGFR translocates to the nucleus and phosphorylates ATM and 
that the CR domain of EGFR is required for ATM interaction upon IR 
stimulation. 
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Figure 6 Endogenous EGFR associates with ATM in the nucleus upon 
IR stimulation. 
A. EGFR translocates to the nucleus after IR stimulation. 
        HeLa cells were serum starved, treated with DMSO or gefitinib, 
and stimulated with or without 10 Gy IR. The resulting cells were 
harvested for nuclear fractionation, followed by co-
immunoprecipitation assays as shown in Figures 6B, 6C and 6D. 
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Figure 6 Endogenous EGFR associates with ATM in the nucleus upon 
IR stimulation. 
B. EGFR associates with ATM in the nucleus. 
        Western blot analyses of endogenous EGFR IP products from 
NE with indicated antibodies. 
 
 
 
C. ATM associates with EGFR in the nucleus. 
        Western blot analyses of endogenous ATM IP products from NE 
with indicated antibodies. 
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Figure 6 Endogenous EGFR associates with ATM in the nucleus upon 
IR stimulation. 
 
D. EGFR fails to interact with ATM in the cytosolic compartment of cell. 
        Western blot analyses of endogenous EGFR IP products from 
CE with indicated antibodies. 
 
 
 
 
E. EGFR C-terminal CR region is required for ATM interaction. 
        Up panel: schematic representation of the EGFR domain 
structure. Myc-tagged EGFR wild type or truncated mutants including 
catalytic region deletion, C-terminal deletion, intra-cellular domain 
deletion or extra-cellular domain deletion are designed as WT, ∆CR, 
∆C-ter, ECD and ICD, respectively. “+” indicates interaction with ATM. 
“-” indicates no interaction with ATM. 
        Bottom panel: HEK 293T cells were transfected with plasmids as 
indicated and harvested for Co-IP assay followed by Western blot 
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analysis after IR stimulation. ECD: extracellular domain. TM: 
transmembrane. JM: juxtamembrane. KD: kinase domain. CR: C-
terminal regulatory region. ICD: intracellular domain. IB: immuno-
blotting. WCE: whole cell extract. 
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CHAPTER 6 EGFR IS RECRUITED TO DSBs IN RESPONSE TO DNA 
DAMAGE STIMULI 
 
6.1 EGFR co-localizes with ATM at I-SceI induced DSBs. 
        ATM is known to be recruited by MRN complex to DSBs in response to 
DSBs formation (Derheimer and Kastan, 2010; Uziel et al., 2003) and we 
found EGFR associates with and phosphorylated ATM upon IR, implying that 
EGFR may be recruited to DSBs like ATM. To investigate whether EGFR is 
recruited to DSBs upon DNA damage stimuli, we first carried out chromatin 
immunoprecipitation (ChIP) combined with PCR in DR-GFP reporter 
integrated U2OS cell system (Figure 7A) (Peng et al., 2009). We found that 
exogenous I-SceI expression induced the recruitment of endogenous EGFR 
to the DSBs (Figure 7B) similar to activated ATM (p-ATM S1981; Figure 7C).  
 
6.2 EGFR is recruited to DSBs in response to laser light activation. 
        Then, using a KillerRed light activation system (Figure 7D; detailed 
information is described in Materials and Methods) that generates DSBs, we 
also showed in Figure 7E that GFP-tagged EGFR signal (indicated by yellow 
arrowheads in the lower panels) overlapped with tetR-KillerRed (orange color 
in the merged inset), which was not observed in the control (top panels), 
further substantiating the localization of EGFR at DSBs upon laser activation. 
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Together, these data suggest that EGFR, like ATM, is recruited to DSBs 
upon DNA damage stimulation.  
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Figure 7 EGFR is recruited to DSBs in response to DNA damage stimuli. 
A. Schematic representation of DR-GFP reporter integrated in U2OS cell. 
        Full-length GFP expression DNA was truncated by I-SceI 
restriction enzyme recognition sequence (marked as red). With 
exogenous I-SceI expression-induced DNA DSB, homologous 
recombination efficiency can be determined by full-length GFP 
expression by using flow cytometry. 
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Figure7. EGFR is recruited to DSBs in response to DNA damage stimuli. 
B. EGFR is recruited to I-SceI induced DSBs. 
        ChIP assay was performed with anti-EGFR antibodies or IgG in I-
SceI-induced DSBs DR-GFP-integrated U2OS cells. Specific primers 
(marked as red arrows in Figure 7A) flanking I-SceI site were used in 
PCR to detect activated ATM and EGFR localized at DSBs. 
Quantitation of DSB recruitment fold change is presented as mean ± 
SD. n = 3. *p < 0.05. 
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Figure7 EGFR is recruited to DSBs in response to DNA damage stimuli. 
C. Activated ATM is recruited to I-SceI induced DSBs. 
        ChIP assay was performed with p-ATM S1981 (pATM) or IgG in 
I-SceI-induced DSBs DR-GFP-integrated U2OS cells. Specific primers 
(marked as red arrows in Figure 7A) flanking I-SceI site were used in 
PCR to detect activated ATM and EGFR localized at DSBs. 
Quantitation of DSB recruitment fold change is presented as mean ± 
SD. n = 3. *p < 0.05. 
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Figure7 EGFR is recruited to DSBs in response to DNA damage 
stimuli. 
D. Schematic representation of the KillerRed system in U2OS TRE cell. 
        KillerRed is a light-stimulated ROS-inducer fused to a tet-
repressor (tetR-KR), which binds to a TRE cassette (~ 90 kb) 
integrated at a defined genomic locus in U2OS cells (U2OS TRE cell 
line) (Lan et al., 2013; Lan et al., 2010). KR facilitates the formation of 
oxygen radicals and superoxide through the excited chromophore 
(Carpentier et al., 2009; Pletnev et al., 2009) to induce DNA damage. 
By targeting the expression of KR to one specific genome site, we can 
visualize the recruitment of proteins at genetic loci. 
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Figure7 EGFR is recruited to DSBs in response to DNA damage stimuli. 
E. GFP-tagged EGFR is recruited to DSBs in response to laser light. 
        GFP-tagged EGFR and tetR-mcherry or tetR-KR were 
transfected into U2OS TRE cells. The KillerRed spot was activated 
with 559 nm laser to induce DNA damage. Representative images 
after DNA damage induced by KillerRed activation are shown in the 
lower panels. White arrowheads (also shown in enlarged insets): a tet-
repressor fused monomer cherry (tetR-mcherry) binds to a TRE 
cassette integrated at a defined genomic locus in U2OS cells without 
laser light activated DNA damage. Yellow arrowheads (also shown in 
enlarged insets): DNA damage sites induced by a tet-repressor fused 
KillerRed (tetR-KR) expression and light activation as described in 
Figure 7D. 
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CHAPTER 7 EGFR CO-LOCALIZES WITH ATM AND γ-H2AX AT DSBs 
 
7.1 EGFR co-localizes with ATM and γ-H2AX at laser irradiation- 
induced DSBs.         
        To examine whether EGFR co-localizes with ATM or other DDR 
proteins such as γ-H2AX at DSBs, we treated U2OS or HeLa cells by laser 
irradiation (Lan et al., 2005; Lan et al., 2004) and found overlapping signals 
indicative of co-localization between GFP-tagged (yellow arrowheads, Figure 
8A) or endogenous EGFR (yellow arrowheads or enlarged insects, Figure 8B) 
and activated ATM (p-ATM S1981) or γ-H2AX (Figure 8C). The results 
suggested both endogenous and GFP-tagged EGFR are able to be recruited 
to and co-localize with ATM or γ-H2AX at DSBs.  
 
7.2 EGFR associates with MRN complex in the nucleus. 
        As ATM is recruited to DSBs by Mrell-Rad50-NBS1 (MRN) complex 
(Uziel et al., 2003) and activated by MRN in vitro (Lee and Paull, 2004, 2005), 
we suspected whether EGFR can also participate into ATM/MRN complex at 
DSBs. To this end, we showed that EGFR immunoprecipitation can pull 
down the MRN complex in the nuclear extract after IR treatment (Figure 8D). 
These results suggest that EGFR may play a role in DDR by associating with 
ATM and the MRN complex at DSBs upon IR stimulation.  
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs. 
A. GFP-tagged EGFR co-localizes wit ATM at laser irradiation-induced 
DSBs. 
        GFP-tagged EGFR-transfected U2OS cells were irradiated with 
405 nm for 100 ms. After irradiation, cells were fixed and stained with 
p-ATM S1981 antibody. Laser microirradiation-induced DSBs is 
indicated by yellow arrowheads. 
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs. 
B. Endogenous EGFR co-localizes with ATM at laser irradiation-induced 
DSBs. 
        HeLa cells are irradiated with 405 nm for 60 ms. After irradiation, 
cells were fixed and stained with antibodies against EGFR and p-ATM 
S1981. Laser irradiation-induced DSBs are indicated by yellow 
arrowheads (also shown in enlarged insets).  
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs. 
C. GFP-tagged EGFR co-localizes with γ-H2AX at micro-laser IR induced 
DSBs. 
        GFP-EGFR transfected U2OS cells are irradiated with 405 nm for 
100 ms. Fifteen minutes after laser irradiation, cells are fixed and 
stained with indicated antibody. Yellow arrowheads, laser 
microirradiation-induced DSBs. 
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Figure 8 EGFR co-localizes with ATM and other DDR proteins at DSBs. 
D. Nuclear EGFR associates with MRN complex after IR stimulation. 
        Western blotting analysis of endogenous EGFR IP products from 
NE treated with or without IR. NE: nuclear extract. Lamin B: nuclear 
fraction marker. 
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CHAPTER 8 EGFR IS REQUIRED FOR ATM AND CHK2 IRIF 
 
8.1 EGFR is required for ATM IRIF 
        As we demonstrated that EGFR phosphorylates and interacts with ATM 
upon IR, we suspect that EGFR may participate into DDR like ATM and other 
DDR proteins. First, we aimed to determine whether EGFR is required for 
ATM downstream functions, such as irradiation-induced foci formation (IRIF) 
and DNA repair ability, we generated EGFR knockdown pooled stable clones 
using lentiviral-based shRNA targeted against EGFR (up panel, Figure 9A). 
Silencing EGFR impaired p-ATM S1981 IRIF (bottom panel, Figure 9A) and 
chromatin-enriched fractionation also showed that ATM S1981 
phosphorylation levels were lower in EGFR knockdown stable clones from 
two different shRNAs than control cells (Figure 9B). Importantly, pretreatment 
with EGFR kinase inhibitor gefitinib also abolished p-ATM S1981 IRIF 
induced by laser microirradiation (Figure 9C), suggesting EGFR indeed 
required for ATM IRIF. 
 
8.2 Depletion of EGFR impairs CHK2 IRIF 
        CHK2 is one of the major ATM downstream kinase which 
phosphorylates other DDR proteins and mediates cell cycle checkpoints after 
being activated and phosphorylated by ATM at serine 68 (Ward et al., 2001). 
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To test whether EGFR involves in ATM downstream signaling, we found 
depletion of endogenous EGFR impairs CHK2 IRIF (Figure 9D). Together, 
these results indicated that EGFR and its kinase activity are required for ATM 
and CHK2 IRIF in DDR. 
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Figure 9 EGFR is required for ATM and CHK2 IRIF 
A. EGFR is required for ATM IRIF. 
        Up panel: Western blot analysis of control or two different EGFR-
knockdown U2OS cells. Bottom panel: Immunofluorescent (IF) 
staining of irradiation-induced foci (IRIF) of control or EGFR-depleted 
(shEGFR) U2OS cells with indicated antibodies. Quantitation of p-
ATM S1981 and p-CHK2 IRIF is presented as mean ± SD. n =103. *p 
< 0.05. 
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Figure 9 EGFR is required for ATM and CHK2 IRIF 
B. Knocking down endogenous EGFR decreases ATM pS1981 level in 
chromatin enrich fractionation. 
        Chromatin enriched fractionation and WCE of control or EGFR-
knockdown HeLa cells stimulated with or without IR. Control: shRNA 
vector control. #1 and #2 indicate two different clones of shEGFR. 
WCE: whole cell extract. ORC2: origin replication complex 2, serving 
as a chromatin fraction marker. Tubulin: cytosolic marker. 
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Figure 9 EGFR is required for ATM and CHK2 IRIF 
C. EGFR kinase activity is required for ATM IRIF. 
        U2OS cells are treated with or without 10 µM Gefitinib for 16 h 
and irradiated with 405 nm for 100 ms. 15 min after irradiation, cells 
are fixed and stained with indicated antibody. DAPI: 4,6-diamidio-2-
phenylindole. Yellow arrowheads, laser microirradiation-induced DSBs. 
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Figure 9 EGFR is required for ATM and CHK2 IRIF 
D. Depletion of EGFR impairs CHK2 IRIF. 
        Immunofluorescent (IF) staining of irradiation-induced foci (IRIF) 
of control or EGFR-depleted (shEGFR) U2OS cells with indicated 
antibodies. DAPI: 4,6-diamidio-2-phenylindole. 
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CHAPTER 9 EGFR IS REQUIRED FOR ATM-MEDIATED DAN REPAIR 
 
9.1 Knocking down-EGFR reduces DNA repair ability. 
        IRIF of p-ATM S1981 is known to activate or recruit DDR proteins such 
as NBS1 and BRCA1 to DSBs to execute DNA repair (Cortez et al., 1999; 
Kastan and Lim, 2000; Lukas et al., 2011). We next established the link 
between EGFR and DNA repair by carrying out a neutral comet assay, which 
detects DNA damage level as indicated by comet tail movement. The results 
showed that EGFR-silenced cells had four times higher DNA damage levels 
than the control-silenced cells, suggesting that EGFR deficiency reduces 
DNA repair ability (Figure 10A). To substantiate this finding, we compared 
the number of EGFR-knockdown and control cells that contained γ-H2AX foci 
as previous reports have indicated that the kinetics of γ-H2AX foci clearance 
correlates with mammalian cell radio-sensitivity (MacPhail et al., 2003; 
Taneja et al., 2004). Indeed, EGFR-depleted cells demonstrated delayed 
DNA repair efficiency as indicated by a higher percentage of cells containing 
γ-H2AX foci compared with control cells at 24 and 48 h after IR stimulation 
(Figure 10B).  
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9.2 EGFR is required for ATM-mediated homologous recombination 
repair. 
        To further determine whether EGFR is involved in ATM-mediated 
homologous recombination repair (Iijima et al., 2008; Morrison et al., 2000), 
we generated control and EGFR-depleted U2OS cells integrated with DR-
GFP reporter (Figure 7A) (Peng et al., 2009). We found that DSBs induced 
by exogenous I-SceI expression was efficiently repaired, as indicated by the 
number of GFP-expressing cells, in control but not in EGFR-depleted cells 
(Figure 10C). All together, these results suggest that EGFR is required for 
ATM-mediated IRIF and DNA repair. 
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Figure 10 EGFR involves in DNA repair. 
A. Depletion of EGFR impairs DNA repair. 
Comet assay of EGFR-depleted HeLa cells were carried out with or 
without 15 Gy IR. Top: four representative figures showing comet tail 
movements (indicated by red bars) in EGFR knockdown or vector 
control HeLa cells after IR treatment 6 hours. Bottom: quantitation 
from three independent experiments with or without IR exposure. Cells 
were measured by CometScore software in each experiment. n=50. 
**p < 0.01. Western blot analysis of control or EGFR-knockdown HeLa 
cells used in comet assay. Control: EGFR shRNA vector control. 
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Figure 10 EGFR involves in DNA repair. 
B. Knocking-down endogenous EGFR delays DNA repair. 
        Quantification of the percentage of cells with an amount of γ-
H2AX foci after IR in control (shCtrl) or two EGFR-depleted 
(shEGFR#1 and #2) U2OS cells. Cells were exposed to 5 Gy of 
ionizing radiation (IR), fixed after 0, 4 hours, 24 hours and 48 hours 
and stained with DAPI and antibodies against γ-H2AX. Percentage of 
γ-H2AX foci staining positive cells was quantitated among various 
fields. **p < 0.01. 
 
 
 
 
 
65 
 
Figure 10 EGFR involves in DNA repair. 
C. EGFR is required for ATM-mediated homologous recombination repair. 
        Homologous recombination efficiency in DR-GFP reporter-
integrated U2OS cells with control or EGFR silencing (shEGFR #1 
and #2) was determined by flow cytometry after ectopic expression of 
I-SceI. Top: Western blotting showing two EGFR-targeting shRNA #1 
and #2 knockdown efficiency in DR-GFP integrated U2OS cells. 
Bottom: quantitation of three independent experiments. Ctrl: EGFR 
shRNA vector control. *p = 0.02. 
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CHAPTER 10 EGFR MEDIATES ATM Y370 PHOSPHORYLATION 
 
10.1 ATM Y370 is a major EGFR-mediated phosphorylation site. 
        Next, we asked if EGFR phosphorylates ATM at the conserved Y370 
and mediates ATM function through this phosphorylation event. Co-
immunoprecipitation of Myc-tagged EGFR with Flag-tagged ATM in 
HEK293T cells showed that ectopic expression of wild-type (WT) but not 
kinase-dead (KD) mutant EGFR enhanced ATM tyrosine phosphorylation in 
vivo (Figure 11A). Consistently with the above finding in which gefitinib 
pretreatment reduced the association between endogenous EGFR and ATM 
(Figures 6B and 6C), we found that only EGFR WT but not KD mutant 
interacted with Flag-tagged ATM (Figure 11A). This suggests that the kinase 
activity of EGFR is required for its binding with ATM. In addition, the ATM 
Y370F mutant decreased its ability to bind to EGFR as well as its levels of 
tyrosine phosphorylation, further supporting that Y370 serves a major EGFR 
phosphorylation site.  
 
10.2 Generation of AYM pY370 antibody. 
        To investigate the role of Y370 phosphorylation in vivo, we generated a 
specific antibody against ATM Y370 phosphorylation and validated the 
specificity of this antibody in which only the phospho-Y370 peptide but not 
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the non-phospho-Y370 peptide or other phospho-Y peptides was recognized 
(Figure 11B). Using this antibody, we showed that phospho-Y370 level was 
decreased when Flag-tagged Y370F but not WT was co-immunoprecipitated 
with Myc-tagged EGFR (Figure 11C). Moreover, the levels of phospho-Y370 
increased upon IR but reduced when cells were pretreated with gefitinib 
(Figure 11D), suggesting that IR-induced ATM Y370 phosphorylation relies 
on EGFR’s kinase activity.  
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR 
A. ATM Y370 serves as a major EGFR phosphorylation site. 
        HEK 293T cells transfected with the indicated plasmids were 
treated by IR stimulation. The resulting cells were harvested for co-
immunoprecipitation followed by Western blot analysis. 
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR 
B. Characterization of ATM Y370 phosphorylation antibody by using dot 
blotting. 
        Various amounts of peptides were spotted on PVDF membrane 
and detected by p-ATM Y370 antibody or amido black staining. IB: 
immuno-blotting. ATM pY370: ATM phospho-Y370 peptide. ATM 
Y370: ATM non-phospho-Y370 peptide. MCM7 pY600: MCM7 
phospho-600 peptide. Lyn pY32: Lyn phosphor-32 peptide (Huang et 
al., 2013).  
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Figure 11 ATM Y370 phosphorylation is mediated by EGFR 
C. Characterization of ATM Y370 phosphorylation antibody by western 
blotting. 
        HEK 293T cells were transfected with plasmids as indicated and 
harvested for Co-IP assay followed by Western blot analysis after IR 
stimulation. 
 
 
 
 
 
 
 
 
 
 
71 
 
Figure 11 ATM Y370 phosphorylation is mediated by EGFR 
D. Endogenous ATM is phosphorylated at Y370 upon IR. 
        Top: Western blot analysis of endogenous ATM IP products from 
HeLa cell NE treated with or without IR. Gefitinib: EGFR kinase 
activity inhibitor. Bottom: western blot analysis of nuclear fractionation. 
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CHAPTER 11 EGFR MEDIATES DDR via ATM Y370 
PHOSPHORYLATION 
 
11.1 ATM Y370 phosphorylation facilitates ATM IRIF. 
        To validate that ATM Y370 phosphorylation responds to IR and 
orchestrates DDR, Flag-tagged ATM WT or Y370F mutant was restored in 
ATM-depleted HeLa cells to examine its effect on p-ATM S1981 IRIF. As 
shown in Figure 12A, re-expression of ATM WT but not of Y370F mutant 
rescued p-ATM S1981 IRIF. In addition, compared with ATM WT, recruitment 
of ATM Y370F to chromatin induced by IR was significantly reduced as 
demonstrated by chromatin-enriched cell fractionation assay (Figure 12B). 
These findings suggest that EGFR-mediated ATM Y370 phosphorylation 
facilitates p-ATM S1981 IRIF. 
 
11.2 ATM Y370 phosphorylation defective mutant impairs downstream 
CHK2 IRIF and NBS1 S343 phosphorylation. 
        Activated ATM is known to rapidly phosphorylate protein kinase CHK2 
at threonine 68 upon IR stimulation to regulate cell cycle arrest (Ahn et al., 
2000; Matsuoka et al., 2000; Ward et al., 2001; Zhou et al., 2000). To 
decipher whether ATM Y370 phosphorylation plays a role in mediating 
downstream DDR proteins like CHK2, we examined p-CHK2 IRIF in ATM-
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depleted HeLa cells. Re-expression of Flag-tagged ATM WT but not Y370F 
mutant rescued p-CHK2 IRIF (Figure 12C), indicating that ATM Y370 
phosphorylation is also involved in p-CHK2 IRIF. We further investigated 
whether ATM Y370 phosphorylation is also involved S343 phosphorylation of 
NBS1, as ATM serves as an upstream kinase in the ATM-NBS1-SMC1 
signaling for cell cycle checkpoint (Kitagawa et al., 2004; Lim et al., 2000). 
Only Flag-tagged ATM WT but not Y370F in ATM-depleted HeLa cells 
reactivated NBS1 S343 phosphorylation (Figure 12D).  
 
11.3 EGFR regulates DNA-PKcs activation through ATM Y370 
phosphorylation. 
        Emerging data demonstrated DNA-PKcs activation depends on 
association with nuclear EGFR but detailed mechanism is not clear 
(Bandyopadhyay et al., 1998; Dittmann et al., 2005a; Dittmann et al., 2005b). 
A recent report indicated that DNA-PKcs activation relies on ATM S1981 
phosphorylation (Chen et al., 2007). We found that restoration of Flag-tagged 
ATM WT, but not Y370F can rescue DNA-PKcs IRIF, suggesting EGFR 
regulates DNA-PKcs via ATM Y370 phosphorylation (Figure 12E). Together, 
these results suggest that EGFR-mediated ATM Y370 phosphorylation is 
essential for ATM activation, downstream CHK2 and DNA-PKcs IRIF and 
NBS1 S343 phosphorylation. 
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM 
IRIF and downstream signaling 
A. ATM Y370 phosphorylation facilitates ATM IRIF. 
        p-ATM S1981 IRIF staining of ATM-depleted (shATM) HeLa cells 
with reconstitution of Flag-tagged ATM wild type (WT) or Y370F 
mutant.  Quantitation of p-ATM S1981 IRIF is presented as mean 
values ± SD. n =50. **p < 0.01. 
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM 
IRIF and downstream signaling 
B. ATM Y370 phosphorylation defective mutant impairs ATM chromatin 
recruitment. 
        Vector control, Flag-tagged ATM WT, or Y370F was restored in 
ATM-depleted HeLa cells (HeLa shATM). After treatment with or 
without IR and recovery for 4 hours, chromatin enriched fractionation 
was carried out, followed by Western blot analysis with indicated 
antibodies. 
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM 
IRIF and downstream signaling 
C. ATM Y370 phosphorylation involves in CHK2 IRIF. 
        p-CHK2 IRIF staining of ATM-depleted HeLa cells with 
reconstituted Flag-tagged ATM WT or Y370F mutant. Quantitation of 
p-CHK2 IRIF is presented as mean values ± SD. n =50. **p < 0.01. 
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM 
IRIF and downstream signaling 
D. ATM Y370 phosphorylation defective mutant reduces ATM-mediated 
NBS1 S343 phosphorylation. 
ATM-depleted HeLa cells were transfected with Flag-tagged ATM WT, 
Y370F, or vector alone. Cell transfectants were treated with or without 
IR, harvested and analyzed by Western blot with indicated antibody. 
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Figure 12 EGFR mediated ATM Y370 phosphorylation facilitates ATM 
IRIF and downstream signaling 
E. ATM Y370 phosphorylation recues DNA-PKcs IRIF. 
        DNA-PKcs IRIF staining of ATM-depleted HeLa cells with 
reconstituted Flag-tagged ATM WT or Y370F mutant. Quantitation of 
p-DNA-PKcs IRIF is presented as mean values ± SD. n =50. **p < 
0.01. 
 
 
 
 
         
 
  
79 
 
CHAPTER 12 EGFR MEDIATES RADIO-THERAPY RESISTANCE 
THROUGH ATM Y370 PHOSPHORYLATION 
 
12.1 ATM Y370 phosphorylation is essential for ATM-mediated radio-
therapy resistance. 
        Clinically, EGFR inhibitors synergistically sensitize response to radiation 
therapy in patients with head and neck squamous cell carcinoma (Bernier et 
al., 2009). Since EGFR-mediated ATM Y370 phosphorylation is required for 
ATM activation, downstream signaling, and DNA repair, we hypothesized 
that ATM Y370 phosphorylation plays a role in radiotherapy resistance. 
Indeed, HeLa cell colony formation was reduced in ATM-depleted cells 
compared to that in control cells after IR stimulation but was rescued by 
reconstitution of only ATM WT but not the Y370F mutant (Figures 13A and 
13B), suggesting ATM Y370 phosphorylation is essential for ATM-mediated 
DNA repair and radiotherapy resistance.  
 
12.2 ATM-mediated radio-therapy resistance depends on EGFR kinase 
activity. 
        To show that EGFR regulates radiotherapy resistance through EGFR’s 
kinase activity, we performed colony formation assay by using various doses 
of EGFR kinase inhibitor gefitinib. Consistent with previous findings (Kang et 
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al., 2012; Lin et al., 2011; Park et al., 2010), gefitinib combined with IR also 
produced a synergistic effect in radio-sensitivity (Figure 13C). Collectively, 
our findings uncovered an underlying mechanism by which gefitinib 
enhances radio-sensitivity through EGFR-mediated ATM Y370 
phosphorylation to facilitate ATM activation and subsequent DDR. 
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Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity. 
A. ATM Y370 phosphorylation is essential for ATM-mediated radio-
sensitivity. 
        ATM-depleted HeLa cells were reconstituted with vector control, 
Flag-tagged ATM WT, or Y370F and treated with increasing doses of 
IR. The cell survival rate was determined by colony formation assay 
and presented as mean value ±SD. n = 3. *p < 0.05. **p < 0.01. 
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Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity. 
B. Western blot analysis of ATM-depleted HeLa cells with restoration of 
vector control, Flag-tagged ATM WT or Y370F.  
        Vector control, Flag-tagged ATM WT, or Y370F was restored in 
ATM-depleted HeLa cells (HeLa shATM). After transfection for forty-
eight hours, cell lysates were harvested for Western blot analysis with 
indicated antibodies. 
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Figure 13 ATM Y370 phosphorylation regulates radio-sensitivity. 
C. EGFR kinase activity is required for ATM-mediated radiosensitivity. 
        Colony-forming assay of HeLa cells treated with the indicated 
concentration of gefitinib with increasing doses of IR. The cell survival 
rate was presented as mean value ±SD. n = 3. **p < 0.01. 
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CHAPTER 13 SUMMARY AND DISCUSSION 
 
13.1 Summary 
        Ataxia telangiectasia-mutated (ATM) functions as one of the upstream 
serine/threonine kinases in DNA damage response. Upon formation of DNA 
double strand breaks (DSBs), ATM is rapidly activated and 
autophosphorylated at serine 1981 which then mediates downstream 
signaling pathway. However, how ATM is regulated remains unclear. As 
shown in the model below (Figure 14), we demonstrate that  
1. ATM associates with and is phosphorylated at tyrosine 370 (Y370) by 
nuclear epidermal growth factor receptor (EGFR) upon IR stimulation.  
2. ATM co-localizes with EGFR at DSBs by using multiple methods 
including chromatin immunoprecipitation, KillerRed system, and laser 
irradiation.  
3. Knocking down EGFR or EGFR kinase inhibitor gefitinib treatment not 
only impairs ATM and downstream CHK2 and DNA-PKcs foci 
formation but also reduces DNA repair efficiency.  
4. EGFR-mediated ATM Y370 phosphorylation facilitates ATM, DNA-
PKcs  and CHK2 foci formation, NBS1 phosphorylation, and enhances 
radiotherapy resistance.  
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Together, we unravel an EGFR mediated novel mechanism of ATM 
activation, downstream signal transduction, and DNA repair efficiency.  
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Figure 14 Propose model showing the role of EGFR in ATM-mediated 
DNA damage response. 
EGFR-mediated ATM Y370 phosphorylation facilitates ATM S1981 
autophosphorylation (indicated by “+”) and ATM-mediated DNA damage 
response such as DNA-PKcs and CHK2 IRIF. Pretreatment of EGFR kinase 
inhibitor (gefitinib) blocks ATM Y370 phosphorylation reduces ATM S1981 
autophosphorylation and impairs ATM-mediated DNA damage response. 
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13.2 The role of EGFR in cancer cell radio-sensitivity. 
        The current report reveals a tyrosine phosphorylation of ATM at Y370 
by EGFR after IR stimulation. The ATM Y370 phosphorylation event 
facilitates not only ATM activation but also ATM-mediated downstream DDR 
(Figure 14). Our data indicate that EGFR-mediated ATM Y370 
phosphorylation confers radiotherapy resistance in cancer cells and suggest 
ATM phospho-Y370 could serve as a marker to stratify patients for rational 
combinational therapy of IR and TKI treatment.  
        Two different groups have previously reported that erlotinib or gefitinib 
pretreatment increases radio-sensitivities of triple-negative breast cancer 
(TNBC) and non-small cell lung cancer (NSCLC) cells, respectively (Lee et 
al., 2012; Park et al., 2010). The data presented in these studies substantiate 
the role of EGFR kinase activity in radiotherapy resistance by demonstrating 
that inactivation of EGFR kinase activity enhances radio-sensitivities of 
TNBC and NSCLC cells. In fact, Das and colleagues demonstrated EGFR 
tyrosine kinase domain mutants in NSCLC cells impaired radiation-induced 
EGFR nuclear translocation and significantly delayed DSB repair efficiency 
(Das et al., 2007), further providing evidence to support the role of nuclear 
EGFR in DDR in our study. Together, our results and other group’s data all 
indicate that EGFR kinase activity plays an important role in mediating 
various types of cancer cell radio-sensitivity. 
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13.3 Tyrosine kinases mediate ATM signaling. 
        In 2013, Jackson’s group demonstrated that c-Abl regulates ATM 
signaling through Y44 phosphorylation of the protein acetyltransferase KAT5 
(also known as TIP60), which increases the acetylation level of ATM (Kaidi 
and Jackson, 2013). We showed that pretreatment of c-Abl kinase inhibitor 
imatinib did not reduce ATM tyrosine phosphorylation as opposed to EGFR 
kinase inhibitors gefitinib and AG1478 (Figure 5A), suggesting that c-Abl may 
not regulate ATM signaling by direct phosphorylation of ATM. Thus, tyrosine 
kinase such as EGFR can directly phosphorylate ATM or like c-Abl can 
indirectly regulate ATM through phosphorylation of KAT5. 
 
13.4 The connections among ATM, DNA-PKcs and EGFR. 
        EGFR has been reported to associate with DNA-PKcs, one of the major 
serine/threonine kinases in DDR, to mediate non-homologous end joining 
after IR, but the detailed mechanism remains unclear (Bandyopadhyay et al., 
1998; Dittmann et al., 2005a). Chen and colleagues also demonstrated that 
activated ATM is essential for DNA-PKcs activation (Chen et al., 2007). They 
found that endogenous ATM-depleted cells mediated by shRNA or A-T cells 
decreases DNA-PKcs threonine 2609 (T2609) phosphorylation, which is 
critical for its role in DSB repair and radiation resistance. Here, we identified 
a mechanism in DNA-PKcs IRIF in DDR through EGFR-mediated Y370 
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phosphorylation of ATM, filling the gap between ATM signaling and DNA-
PKcs T2609 phosphorylation. Taken together, our findings indicate that 
EGFR plays a critical role in DDR and that phospho-ATM-Y370 has the 
potential to serve as a biomarker in radiotherapy or chemotherapy combined 
with targeted EGFR inhibitors in cancer treatments. 
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CHAPTER 14 FUTURE DIRECTIONS 
 
14.1 Hit and stay model 
        Our results indicate EGFR associates and co-localizes with ATM at 
DSBs upon IR stimulation (Figures 6B, 6C and 8B). Interestingly, we found 
that ATM Y370F, a phosphorylation defective mutant of ATM, impairs 
association with Myc-tagged EGFR in co-IP experiment (Figure 11A) and 
pretreatment of EGFR kinase inhibitor gefitinib also reduces interaction 
between endogenous EGR and ATM (Figures 6B and 6C), suggesting both 
EGFR kinase activity and ATM Y370 phosphorylation are required for EGFR-
ATM interaction. These findings raise our interest to figure out whether 
EGFR mediates ATM and other DDR proteins through a “Hit and Stay model”.  
        In this Hit and Stay model, we hypothesize that EGFR binds to and 
phosphorylates ATM at Y370 in response to DSBs induction. Instead of 
leaving the protein complex, EGFR keeps binding with the protein complex 
and further phosphorylates other DDR proteins located at DSBs. Indeed, we 
showed that EGFR not only associates with ATM but also MRN (Mre11-
Rad50-NBS1) complex in the nucleus after IR treatment (Figure 8D). MRN 
complex serves as a critical component in DDR by accumulating at DSBs in 
a very short time after DSBs formation, tethering broken DNA ends, and 
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recruiting more DDR proteins like ATM or γ-H2AX to DSBs for subsequently 
signal transduction (Bensimon et al., 2011; Williams et al., 2010). 
        To current knowledge, three tyrosine phosphorylation sites (Y16, Y197 
and Y429) of NBS1 and Y1125 phosphorylation of Rad50 were identified by 
mass spectrometry carried out by different groups (Chen et al., 2009; Li et al., 
2009b; Olsen et al., 2010; Phanstiel et al., 2011; Rigbolt et al., 2011). 
However, tyrosine kinases responsible for those phosphorylation events or 
subsequent detailed functions in DDR are not clear. It requires further 
experiments to elucidate whether EGFR phosphorylates those DDR proteins 
and contributes their functions in DDR. 
 
14.2 ATM conformational changes in response to DSBs formation. 
        ATM is known to be activated by inductions of DSBs formation, 
dissociated from inactive homodimer to active monomer and 
autophosphorylated at S367, S1893, and S1981 (Bakkenist and Kastan, 
2003; Bensimon et al., 2011; Kozlov et al., 2011). However, how dimeric and 
inactive ATM dissociating as monomeric ATM with activity in response to 
chromosome structural changes remains unclear. In current report, we 
demonstrated that phosphorylation defective mutant ATM, Y370F, fails to 
associate with EGFR (Figure 11A) and impairs ATM and downstream CHK2 
IRIF (Figures 12A and 12C), implying EGFR-mediating ATM Y370 
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phosphorylation may participate into activation and dissociation of dimeric 
ATM.  
        To investigate whether ATM Y370 phosphorylation is required for 
dimeric ATM dissociation, we can purify recombinant Flag-tagged ATM WT 
and HA-tagged ATM Y370F proteins from 293T transfectants cells (Lee and 
Paull, 2004). After sequential purification, we can analyze those ATM protein 
compositions by using native gel electrophoresis followed by western blotting. 
Besides, those purified ATM proteins can be used in in vitro binding assay 
with MRN protein complex and the results may bring us hints regarding the 
connections in those DDR proteins. 
 
14.3 Combination therapy of targeting nuclear EGFR and radiation 
        Nuclear EGFR had been linked to tumor progression, poor prognosis, 
radiotherapy resistance in types of cancer (Brand et al., 2013; Wang et al., 
2010). Previous reports indicated that PKCε-mediated EGFR Y654 
phosphorylation, Src family kinase (SFK)-mediated EGFR Y1101 
phosphorylation and AKT-mediated EGFR S229 phosphorylation all 
contribute to EGFR nuclear translocation in human NSCLC and breast 
cancer (Huang et al., 2011; Iida et al., 2013; Li et al., 2009a). Our findings 
indicate nuclear EGFR-mediated ATM Y370 phosphorylation is essential for 
radiotherapy resistance (Figures 13A and 13C). Therefore, we hypothesize 
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impeding EGFR nuclear translocation by using inhibitors targeting PKCε, 
SFK and AKT may sensitize cancer cell to radiation treatment. 
        To this end, we can first test whether PKCε inhibitors Enzastaurin, 
Midostaurin, SFK inhibitor Dasatinib and AKT inhibitor MK2206 block 
radiation-induced EGFR nuclear translocation and ATM Y370 
phosphorylation. Next, we can further investigate whether combination of 
those inhibitors with radiation enhance cancer cell radiotherapy sensitivity in 
vivo and in vitro. Collectively, blockade of EGFR nuclear translocation 
combines with radiation may benefit radiotherapy or chemotherapy resistant 
cancer patients and improve their survival rate in the future. 
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